BIOFRONTERA INC (BFRI)
US09077D2099 - Common Stock
Biofrontera Inc. Reports Third Quarter and Nine-Month 2024 Financial Results and Provides Business Update
●Total revenues for the third quarter 2024 were $9.0 million, an increase of 1.5% from Q3 2023. Revenue increase would have been 19% if shipments were not...
Biofrontera Inc. to Report Third Quarter Financial Results on November 13, 2024
Biofrontera Inc. Announces Highly Significant Results In Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) Regarding The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
First Phase 3 PDT study in patients with sBCC in the United States.Primary and secondary endpoints all highly statistically significant...
Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)
First Phase 3 PDT study in patients with sBCC in the United States.Rigorous dual endpoints requiring complete clinical and cytological clearance of...
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz®-PDT using the BF-RhodoLED or the RhodoLED XL...
Biofrontera to Present at the 3rd Annual ROTH Healthcare Opportunities Conference
BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024
BFRI stock results show that Biofrontera beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biofrontera (NASDAQ:BFRI) just reported results for the second quarter of 2024....
Biofrontera Inc. Reports Second Quarter 2024 Financial Results and Provides a Business Update
Woburn, MA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the
Biofrontera Inc. to Report Second Quarter Financial Results on August 14, 2024
Biofrontera Announces the Launch of a New, FDA-Approved Red Light Source, the RhodoLED® XL Lamp
The RhodoLED XL is approved by the FDA in combination with Ameluz® (aminolevulinic acid hydrochloride) topical gel, 10% for photodynamic therapy (PDT) of...
BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 2024
BFRI stock results show that Biofrontera missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
BFRI Stock Earnings: Biofrontera Misses EPS, Misses Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biofrontera (NASDAQ:BFRI) just reported results for the first quarter of 2024.B...
Biofrontera Inc. Reports First Quarter 2024 Financial Results and Provides a Business Update
Biofrontera Inc. to Report First Quarter 2024 Financial Results on May 15, 2024
3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 Million
If you want the chance at possible absurd returns, then consider gambling on these stocks to turn $1,000 into $1 million.
BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023
BFRI stock results show that Biofrontera beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.
BFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biofrontera (NASDAQ:BFRI) just reported results for the fourth quarter of 2023....
Biofrontera Inc. Reports Record Fiscal Year 2023 Financial Results and Provides a Business Update